Dimensional Stability and Process Capability of an Industrial Component Injected with Recycled Polypropylene

The usage of recycled polymers for industrial purposes arises as one of the most promising methods of reducing environmental impact and costs associated with scrapping parts. This paper presents a systematic study of the dimensional stability of a raw and 100% recycled polypropylene subjected to realistic environmental conditions occurring along its working life. The component studied is an internal part of an induction hob assembly. Industrial samples manufactured with both materials, in the same mold, and in the same injection machine, are subjected to ejection conditions, storage conditions (50 °C), and extreme performance conditions (80 °C). Induced dimensional changes are registered and analyzed using a coordinate measuring machine, and a tactile sensing probe. To verify the process capability of the samples manufacturing, Cp and Cpk values are calculated to evaluate the suitability of the recycled material as an alternative. Results conclude that, although the use of recycled material implies slight differences in terms of dimensional stability due to the changes induced in the polymer structure, these differences are not significant enough to affect the injection process capability. Therefore, recycling arises as one effective method to reduce both overruns associated with the consumption of raw polypropylene material and its environmental impact

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)